Home » Novavax to Cut 40 Sales Positions
Novavax to Cut 40 Sales Positions
In a press release, the
biopharmaceutical company said the reductions will allow
the company to prepare for a planned partnership of Estrasorb, its
topical emulsion
for estrogen therapy. The reductions will also more efficiently align
the number
of sales representatives required to support the existing base of
Estrasorb
prescribing physicians while allowing the company to continue to cover
the highest
prescribing obstetricians and gynecologists to grow sales of its
women's health
products.
iWon
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May